Respiratory Disease
Home / Products / Colloidal Gold Platform / Respiratory Disease / Influenza A+B Rapid Test

Influenza A+B Rapid Test

The Influenza A+B Rapid Test Cassette is a rapid chromatographic immunoassay for the qualitative detection of influenza A and B antigens in Nasopharyngeal /nasal swab aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections.

Contact Us
Product Features

Product Highlights:

Easy to use.

Accurate results are available within 15 minutes.

Product Specification

PERFORMANCE CHARACTERISTICS

Sensitivity, Specificity, and Accuracy

The Influenza A+B Rapid Test Cassette(Nasopharyngeal/nasal swab)has been evaluated with specimens obtained from the patients. RT-PCR is used as the reference method for The Influenza A+B Rapid Test Cassette(Nasopharyngeal/nasal swab).  Specimens were considered positive if RT-PCR indicated a positive result.

 

Type A

Type B

RT-PCR

Total

RT-PCR

Total

Positive

Negative

Positive

Negative

Flu A+B Rapid

Test Cassette

Positive

68

14

82

49

7

56

Negative

10

242

252

4

274

278

Total

78

256

334

53

281

334

Relative Sensitivity

87.2%

92.5%

Relative Specificity

94.5%

97.5%

Accuracy

92.8%

96.7%

 

Ref

Specification

WI-FLU-C82-1

1 test/kit

WI-FLU-C82-25

25tests/kit

Feedback
Send
Zhejiang Wantaifu Biotechnology Co., Ltd.
Zhejiang Wantaifu Biotechnology Co., Ltd., established in 2022, is now located in Hangzhou Bay Life Science Park, Economic and Technological Development Zone, Xiaoshan District, Hangzhou. It is an integrated innovative enterprise.

we are China wholesale Influenza A+B Rapid Test manufacturers and OEM Influenza A+B Rapid Test factory. The production center has 100,000-level automatic production lines, which provide effective guarantee for the high precision and high efficiency of products, convenient for customers to do flexible customization, design and processing of precision consumables.

Who

we are

30 Million
Registered capital
130 +
Employees
2022
was founded in
100 Million
Total investment
Our Latest News and Exhibitions